Mediwhale, an AI-based diagnostic solution provider, will provide Reti-CVD for Severance Hospital.

Reti-CVD, nicknamed “Dr. Eye,” is an AI medical device that predicts cardiovascular disease with the same accuracy as cardiac computed tomography (CT) through retinal imaging.

"We are continuing to expand our domestic market by supplying our product to Severance Hospital as the first tertiary general hospital,” Mediwhale CEO Choi Tae-geun said. “We are building medical consensus for Dr. Eye to be established as a standard for cardiovascular disease prevention, and its adoption by Yonsei University Medical System is a very positive sign."

Professor Kim Sung-soo, head of the Department of Ophthalmology at Severance Hospital, said, "As a retina specialist and one of the people who understand the potential of retinal imaging, I think introducing the Dr.Eye test is very significant.”

Kim added that the retina is the only organ in the human body where blood vessels and nerve tissue can be directly observed, and it contains a lot of information related to health.

Noting that predicting cardiovascular disease is just the beginning, Professor Kim said, “The day will come when we can learn about our health and prevent potentially deadly diseases with a single eye scan. We are excited to lead this digital transformation of care."

Meanwhile, Mediwhale recently began preparations to go public by appointing Mirae Asset as the lead underwriter for its initial public offering (IPO).